MS: Experimental Oral Drug Tested
There are 5 types of treatment currently approved for the management
of multiple sclerosis (MS). All are given by injection- intramuscular
or intravenous. They include interferon beta-1a (Avonex, Rebif), interferon
beta-1b (Betaseron), glatirmer acetate (Copaxone), natalizumab
(Tysabri), and mitoxantrone. An oral drug for MS has yet to be approved
by the FDA. However, it appears that based on the test results of at least
one experimental oral drug, that may change soon. According to information
from a two year study, which was presented at a recent meeting of
the American Academy of Neurology, fingolimod (Gilenia) prevented
MS relapses in over 60% of those who received the oral drug compared
to 44% of those who had already received other treatments. Those that
took Gilenia for two years experienced a 30% delay in the disability related
to MS compared to those who took placebo (no treatment).
MS is a condition of the central nervous system. The protective cover
(called myelin) surrounding the nerves is damaged. Symptoms may include
loss of balance, numbness, muscle spasms, weakness, and tremor
in the legs and arms.